TN2017000126A1 - An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof - Google Patents
An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereofInfo
- Publication number
- TN2017000126A1 TN2017000126A1 TN2017000126A TN2017000126A TN2017000126A1 TN 2017000126 A1 TN2017000126 A1 TN 2017000126A1 TN 2017000126 A TN2017000126 A TN 2017000126A TN 2017000126 A TN2017000126 A TN 2017000126A TN 2017000126 A1 TN2017000126 A1 TN 2017000126A1
- Authority
- TN
- Tunisia
- Prior art keywords
- oligosaccharide
- conjugation
- protein
- synthetic
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide - protein (OS-PR) conjugates. The process of synthetic OS-PR conjugation is a rapid process providing oligosaccharide - protein conjugates which are highly irnrnunogenic and elicit specific and hornogenous immune responses. The synthetic oligosaccharide cornprising of four to eight repeating units of respective rnonorners and at least one in-built terminal arnino linker, said synthetic polysaccharide rnimics natural polysaccharide obtained from gram negative bacteria such as Neisseria meningitidis serogroups A, C, Y, W, X and Haemophilus influenzae and carrier protein is obtained from gram positive bacteria such as Clostridiurn tetani ( tetanus toxoid) or Corynebacterium diphtheriae (CRM197) or their recombinant versions. The conjugation chemistry of the said oligosaccharide-protein conjugate of the present invention is thio-ether linkage. The present invention takes complete process tirne in the range of 14-22 hours.The said oligosaccharide-protein conjugates are useful in production of monovalent vaccine or multivalent combination vaccines and as diagnostic tool.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2884DE2014 | 2014-10-09 | ||
PCT/IB2015/057682 WO2016055957A1 (en) | 2014-10-09 | 2015-10-08 | An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2017000126A1 true TN2017000126A1 (en) | 2018-10-19 |
Family
ID=55652678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2017000126A TN2017000126A1 (en) | 2014-10-09 | 2015-10-08 | An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof |
Country Status (18)
Country | Link |
---|---|
US (1) | US10105438B2 (en) |
EP (1) | EP3204396A4 (en) |
JP (1) | JP2017531662A (en) |
KR (1) | KR20170065030A (en) |
CN (1) | CN106795194A (en) |
AU (1) | AU2015329590B2 (en) |
BR (1) | BR112017006447A2 (en) |
CA (1) | CA2963900A1 (en) |
CL (1) | CL2017000844A1 (en) |
CO (1) | CO2017003291A2 (en) |
CU (1) | CU20170046A7 (en) |
EA (1) | EA201700177A1 (en) |
IL (1) | IL251511A0 (en) |
MX (1) | MX2017004495A (en) |
PH (1) | PH12017500579A1 (en) |
SG (1) | SG11201702451WA (en) |
TN (1) | TN2017000126A1 (en) |
WO (1) | WO2016055957A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2865485T3 (en) | 2014-05-24 | 2021-10-15 | Biological E Ltd | New semi-synthetic meningococcal conjugate vaccine |
WO2017017509A1 (en) * | 2015-07-28 | 2017-02-02 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel neisseria meningitidis serogroup y oligomer and process for synthesizing thereof |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
KR20240018697A (en) | 2017-06-10 | 2024-02-13 | 인벤트프라이즈 인크. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
KR20200141053A (en) * | 2018-03-23 | 2020-12-17 | 코라넥스 캐피탈 | Precision sugar conjugates as therapeutic tools |
CN113274488B (en) * | 2021-04-30 | 2023-08-29 | 山东省药学科学院 | Oligosaccharide vaccine for specifically preventing fungal infection and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2434668A1 (en) * | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
ES2533248T3 (en) * | 2005-05-06 | 2015-04-08 | Novartis Ag | Immunogens for vaccines against Meningitidis A |
FR2904627B1 (en) * | 2006-08-04 | 2008-11-07 | Pasteur Institut | NOVEL ACTIVE, PURIFIED AND ISOLATED PEPTIDES, CD4 RECEPTOR DERIVATIVES (MINI-CD4) AND THEIR PREPARATION PROCESS |
CA2819366A1 (en) * | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
-
2015
- 2015-10-08 BR BR112017006447A patent/BR112017006447A2/en not_active Application Discontinuation
- 2015-10-08 TN TN2017000126A patent/TN2017000126A1/en unknown
- 2015-10-08 CA CA2963900A patent/CA2963900A1/en not_active Abandoned
- 2015-10-08 CU CUP2017000046A patent/CU20170046A7/en unknown
- 2015-10-08 JP JP2017518942A patent/JP2017531662A/en active Pending
- 2015-10-08 AU AU2015329590A patent/AU2015329590B2/en not_active Expired - Fee Related
- 2015-10-08 CN CN201580054739.3A patent/CN106795194A/en active Pending
- 2015-10-08 EA EA201700177A patent/EA201700177A1/en unknown
- 2015-10-08 WO PCT/IB2015/057682 patent/WO2016055957A1/en active Application Filing
- 2015-10-08 SG SG11201702451WA patent/SG11201702451WA/en unknown
- 2015-10-08 EP EP15849268.6A patent/EP3204396A4/en not_active Withdrawn
- 2015-10-08 MX MX2017004495A patent/MX2017004495A/en unknown
- 2015-10-08 US US15/516,445 patent/US10105438B2/en not_active Expired - Fee Related
- 2015-10-08 KR KR1020177012154A patent/KR20170065030A/en unknown
-
2017
- 2017-03-29 PH PH12017500579A patent/PH12017500579A1/en unknown
- 2017-04-02 IL IL251511A patent/IL251511A0/en unknown
- 2017-04-04 CO CONC2017/0003291A patent/CO2017003291A2/en unknown
- 2017-04-06 CL CL2017000844A patent/CL2017000844A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20170246313A1 (en) | 2017-08-31 |
US10105438B2 (en) | 2018-10-23 |
EA201700177A1 (en) | 2017-07-31 |
CA2963900A1 (en) | 2016-04-14 |
AU2015329590B2 (en) | 2019-08-22 |
MX2017004495A (en) | 2017-12-18 |
KR20170065030A (en) | 2017-06-12 |
CO2017003291A2 (en) | 2017-06-30 |
CN106795194A (en) | 2017-05-31 |
AU2015329590A1 (en) | 2017-05-04 |
IL251511A0 (en) | 2017-05-29 |
EP3204396A4 (en) | 2018-03-28 |
PH12017500579A1 (en) | 2017-08-30 |
JP2017531662A (en) | 2017-10-26 |
CU20170046A7 (en) | 2017-06-05 |
SG11201702451WA (en) | 2017-04-27 |
WO2016055957A1 (en) | 2016-04-14 |
EP3204396A1 (en) | 2017-08-16 |
BR112017006447A2 (en) | 2017-12-12 |
CL2017000844A1 (en) | 2017-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2017000126A1 (en) | An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof | |
MX2020002558A (en) | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein. | |
MX2023001947A (en) | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates. | |
MX2022009928A (en) | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates. | |
MX2022014850A (en) | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates. | |
PH12018501517B1 (en) | Neisseria meningitidis compositions and methods thereof | |
MX2022009927A (en) | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates. | |
JOP20200141A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
PE20220774A1 (en) | GROUP B STREPTOCOCCO PROTEIN-POLYSACCHARIDE CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGEN COMPOSITIONS COMPRISING CONJUGATES, AND THEIR USES | |
PE20161095A1 (en) | IMMUNOGENIC COMPOSITIONS INCLUDING CONJUGATED CAPSULAR SACCHARID ANTIGENS AND THE USE OF THE SAME | |
MX2020002555A (en) | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates. | |
MX2018010920A (en) | Novel polysaccharide-protein conjugates and process to obtain thereof. | |
GB2455447A (en) | Method of producing meningococcal meningitis vaccine for neisseria meningitidis serotypes A, C,Y and W-135 | |
IN2014DN09791A (en) | ||
PH12016500360A1 (en) | A bacterial vaccine and methods for manufacture thereof | |
MX354103B (en) | Immunogenic composition. | |
BR112015004593A2 (en) | immunogenic compositions | |
MX2020002084A (en) | Peptide conjugates, conjugation process, and uses thereof. | |
MY194920A (en) | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof | |
MX2015013401A (en) | Method of treatment. | |
TH179730A (en) | Improved processes of conjugate (conjugate) and new synthetic conjugates of oligosaccharides - proteins derived of these substances. | |
BR112018001425A2 (en) | new serogroup y oligomers of neisseria meningitidis and their synthesis processes | |
IN2014MU00349A (en) | ||
WO2007087758A3 (en) | Mimotopes of capsular polysaccharides of neisseria meningitidis and pharmaceutical formulations |